

Claim 3 (original) The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 10, 11, 12, 16, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, and 33.

Claim 4 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (original) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Toll-like receptor 4.

Claim 12 (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original) The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original) A method of inhibiting the expression of Toll-like receptor 4 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of Toll-like receptor 4 is inhibited.

Claim 16 (original) A method of treating an animal having a disease or condition associated with Toll-like receptor 4 comprising administering to said animal a therapeutically or prophylactically effective amount of compound of claim 1 so that expression of Toll-like receptor 4 is inhibited.

Claim 17 (original) The method of claim 16 wherein the condition is an inflammatory disorder.

Claim 18 (original) The method of claim 16 wherein the condition involves an immune response.

Claim 19 (original) The method of claim 18 wherein the immune response is Th1 response.

Claim 20 (original) A method of claim 18 wherein the immune response is a Th2 response.

Claim 21 (new) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a 5'-untranslated region (5'UTR) of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 22 (new) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a start region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 23 (new) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a coding region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 24 (new) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a stop region of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 25 (new) The compound of claim 1, wherein said compound comprises an antisense oligonucleotide that is specifically hybridizable with a 3'-untranslated region (3'UTR) of the nucleic acid molecule encoding Toll-like receptor 4.

Claim 26 (new) The compound of claim 1, wherein said compound inhibits the expression of Toll-like receptor 4 by at least 50%.

Claim 27 (new) The compound of claim 1, wherein said compound inhibits the expression of Toll-like receptor 4 by at least 70%.
